Study of INCB123667 in Subjects With Advanced Solid Tumors

Exclusion Criteria

• •History of clinically significant or uncontrolled cardiac disease.
• •History or presence of an ECG abnormality that, in the investigator's opinion, is clinically meaningful.
• •Presence of chronic or current active infectious disease requiring systemic antibiotic, antifungal, or antiviral treatment.
• •Untreated brain or central nervous system (CNS) metastases or brain or CNS metastases that have progressed.
• •Known additional malignancy that is progressing or requires active treatment, or history of other malignancy within 2 years of the first dose of study drug.
• •Specific laboratory values.
• •Significant concurrent, uncontrolled medical conditions, including but not limited to Hepatic and Gastrointestinal.
• •Has not recovered to ≤ Grade 1 from toxic effects of prior therapy and/or complications from prior surgical intervention before starting study drug.
• •Prior treatment with any CDK2 inhibitor.
• •Any change in endocrine therapy within 5 half-lives or 28 days (whichever is shorter) before the first dose of study drug or any administration of targeted therapy, antibody, or hypomethylating agent to treat the participant's disease within 5 half-lives or 28 days (whichever is shorter) before the first dose of study drug.
• •Any major surgery within 28 days before the first dose of study drug.
• •Any prior radiation therapy within 28 days before the first dose of study drug.
• •Undergoing treatment with another investigational medication or having been treated with an investigational medication within 5 half-lives or 28 days (whichever is shorter) before the first dose of study drug.
• •Active HBV or HCV infection that requires treatment.
• •Known history of HIV.
• •Known hypersensitivity or severe reaction to any component of study treatment or formulation components.